Calquence met primary efficacy endpoint in head-to-head ...
Calquence (acalabrutinib) is a next-generation, selective inhibitor of BTK. Calquence binds covalently to BTK, thereby inhibiting its activity. 8,9 In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. 8
DA: 43 PA: 8 MOZ Rank: 67